GW Pharmaceuticals to file Sativex in Europe for spasticity in MS
This article was originally published in Scrip
Executive Summary
GW Pharmaceuticals is to file its cannabis extract CB1 agonist Sativex in the EU in the second quarter as an adjunctive therapy for patients with spasticity due to multiple sclerosis who have achieved inadequate relief with existing therapies after the success of a pivotal Phase III trial.